The confirmatory population for the primary endpoint analysis was the interim per protocol population ( n = 377 ; 188 [ 9 mg OD ] , 189 [ 3mg TID ] ) , in which the primary endpoint was statistically non-inferior with budesonide 9 mg OD versus 3 mg TID .